DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move?

DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year. The U.S. market drove much of this growth, achieving a 15% increase in revenue, fueled by robust demand and broader access to their continuous glucose monitoring (CGM) systems. DexCom’s strategic focus on expanding their prescriber base and enhancing commercial reach has begun to manifest in increased customer acquisition, particularly in the type 2 diabetes sector, where their coverage has expanded significantly.